JCR Pharmaceuticals Co., Ltd. (JCR) will contribute to the development of a sustainable society through business activities based on its corporate philosophy of “Contributing towards people’s healthcare through pharmaceutical products.”
Since its inception in 1975, JCR has sought to create groundbreaking therapeutics that respond to unmet medical needs, particularly in the rare disease field, under its corporate philosophy of “Contributing towards people’s healthcare through pharmaceutical products.” To this end, we have been harnessing forward-looking biotechnologies, as well as technologies for cell therapy and regenerative medicine.
The global environment and conditions and issues facing society have been changing year by year, but JCR believes that it is crucial to create sustained corporate value through its business activities as a pharmaceutical manufacturer and contribute to the development of a sustainable society, and is proactively implementing activities in the core areas of Rare Diseases (RD), Environment (E), Society (S), and Corporate Governance (G).
JCR newly established the Sustainability Advisory Committee, Sustainability Committee and Environmental Committee in July 2022 to enable in-depth discussions and formulating strategies in close alignment with management in response to the ever-changing social and business environment and challenges surrounding JCR. Under the new promotion structure, JCR will continue to work as one team, driven by a sense of purpose in the rare disease field, to pursue sustainability in the manner unique to JCR.
JCR believes that partnership and cooperation with the international community are the most important priorities for realizing sustainability.
In the course of advancing these initiatives, JCR has linked its activities to the 17 goals laid out in the SDGs, in keeping with the spirit of “No one will be left behind.” It shares with and returns to a wide range of stakeholders the achievements of these efforts.